Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2024 Oct 1;97(4):541-545.
doi: 10.1097/TA.0000000000004345. Epub 2024 Apr 30.

Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study

Jordan M Estroff  1 , Joseph Devlin, Lara Hoteit, Adnan Hassoune, Matthew D Neal, Joshua B Brown, Liling Lu, Shannon Kotch, Joshua P Hazelton, Ashton B Christian, Eric O Yeates, Jeffry Nahmias, Lewis E Jacobson, Jamie Williams, Kevin M Schuster, Rick O'Connor, Gregory R Semon, Angela D Straughn, Daniel Cullinane, Tanya Egodage, Michelle Kincaid, Allison Rollins, Richard Amdur, Babak Sarani
Affiliations
Comparative Study

Four-factor prothrombin complex concentrate is not inferior to andexanet alfa for the reversal or oral factor Xa inhibitors: An Eastern Association for the Surgery of Trauma multicenter study

Jordan M Estroff et al. J Trauma Acute Care Surg. .

Abstract

Background: Andexanet alfa (AA) is the only FDA-approved reversal agent for apixaban and rivaroxaban (DOAC). There are no studies comparing its efficacy with four-factor prothrombin complex concentrate (PCC). This study aimed to compare PCC to AA for DOAC reversal, hypothesizing noninferiority of PCC.

Methods: We performed a retrospective, noninferiority multicenter study of adult patients admitted from July 1, 2018, to December 31, 2019, who had taken a DOAC within 12 hours of injury, were transfused red blood cells (RBCs) or had traumatic brain injury, and received AA or PCC. Primary outcome was PRBC unit transfusion. Secondary outcome with intensive care unit length of stay. MICE imputation was used to account for missing data and zero-inflated Poisson regression was used to account for an excess of zero units of RBC transfused. Two units difference in RBC transfusion was selected as noninferior.

Results: Results: From 263 patients at 10 centers, 77 (29%) received PCC and 186 (71%) AA. Patients had similar transfusion rates across reversal treatment groups (23.7% AA vs. 19.5% PCC) with median transfusion in both groups of 0 RBC. According to the Poisson component, PCC increases the amount of RBC transfusion by 1.02 times (95% confidence interval, 0.79-1.33) compared with AA after adjusting for other covariates. The average amount of RBC transfusion (nonzero group) is 6.13. Multiplying this number by the estimated rate ratio, PCC is estimated to have an increase RBC transfusion by 0.123 (95% confidence interval, 0.53-2.02) units compared with AA.

Conclusion: PCC appears noninferior to AA for reversal of DOACs for RBC transfusion in traumatically injured patients. Additional prospective, randomized trials are necessary to compare PCC and AA for the treatment of hemorrhage in injured patients on DOACs.

Level of evidence: Therapeutic/Care Management; Level III.

PubMed Disclaimer

References

    1. Allison TA, Lin PJ, Gass JA, Chong K, Prater SJ, Escobar MA, Hartman HD. Evaluation of the use of low-dose 4-factor prothrombin complex concentrate in the reversal of direct Oral anticoagulants in bleeding patients. J Intensive Care Med . 2020;35:903–908.
    1. FDA approval of Andexanet alfa. Available at: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-produ... . Accessed March 24, 2022.
    1. Connolly SJ, Milling TJ Jr., Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med . 2016;375:1131–1141.
    1. Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, Yue P, Bronson MD, Lu G, Conley PB, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med . 2019;380:1326–1335.
    1. Hunt BJ, Neal MD, Stensballe J. Reversing anti-factor Xa agents and the unmet needs in trauma patients. Blood . 2018;132:2441–2445.

MeSH terms

LinkOut - more resources